Literature DB >> 31493490

Mechanisms of Below-Level Pain Following Spinal Cord Injury (SCI).

Chuck Vierck1.   

Abstract

Mechanisms of below-level pain are discoverable as neural adaptations rostral to spinal injury. Accordingly, the strategy of investigations summarized here has been to characterize behavioral and neural responses to below-level stimulation over time following selective lesions of spinal gray and/or white matter. Assessments of human pain and the pain sensitivity of humans and laboratory animals following spinal injury have revealed common disruptions of pain processing. Interruption of the spinothalamic pathway partially deafferents nocireceptive cerebral neurons, rendering them spontaneously active and hypersensitive to remaining inputs. The spontaneous activity among these neurons is disorganized and unlikely to generate pain. However, activation of these neurons by their remaining inputs can result in pain. Also, injury to spinal gray matter results in a cascade of secondary events, including excitotoxicity, with rostral propagation of excitatory influences that contribute to chronic pain. Establishment and maintenance of below-level pain results from combined influences of injured and spared axons in the spinal white matter and injured neurons in spinal gray matter on processing of nociception by hyperexcitable cerebral neurons that are partially deafferented. A model of spinal stenosis suggests that ischemic injury to the core spinal region can generate below-level pain. Additional questions are raised about demyelination, epileptic discharge, autonomic activation, prolonged activity of C nocireceptive neurons, and thalamocortical plasticity in the generation of below-level pain. PERSPECTIVE: An understanding of mechanisms can direct therapeutic approaches to prevent development of below-level pain or arrest it following spinal cord injury. Among the possibilities covered here are surgical and other means of attenuating gray matter excitotoxicity and ascending propagation of excitatory influences from spinal lesions to thalamocortical systems involved in pain encoding and arousal.
Copyright © 2019 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Spinal cord injury; below-level pain; central pain; deafferentation pain; spinothalamic cordotomy

Year:  2019        PMID: 31493490     DOI: 10.1016/j.jpain.2019.08.007

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  5 in total

1.  Depolarization-Dependent C-Raf Signaling Promotes Hyperexcitability and Reduces Opioid Sensitivity of Isolated Nociceptors after Spinal Cord Injury.

Authors:  Anibal Garza Carbajal; Alexis Bavencoffe; Edgar T Walters; Carmen W Dessauer
Journal:  J Neurosci       Date:  2020-07-20       Impact factor: 6.167

2.  Prevalence of Spasticity and Below-Level Neuropathic Pain Related to Spinal Cord Injury Level and Damage to the Lower Spinal Segments.

Authors:  Bengt Skoog; Karl-Erik Jakobsson
Journal:  J Rehabil Med Clin Commun       Date:  2020-03-08

Review 3.  The Impact of Activity-Based Interventions on Neuropathic Pain in Experimental Spinal Cord Injury.

Authors:  Jing Chen; Norbert Weidner; Radhika Puttagunta
Journal:  Cells       Date:  2022-09-30       Impact factor: 7.666

4.  Myelination of Callosal Axons Is Hampered by Early and Late Forelimb Amputation in Rats.

Authors:  Rodrigo Vianna-Barbosa; Carlomagno P Bahia; Alexandre Sanabio; Gabriella P A de Freitas; Rodrigo F Madeiro da Costa; Patricia P Garcez; Kildare Miranda; Roberto Lent; Fernanda Tovar-Moll
Journal:  Cereb Cortex Commun       Date:  2020-11-27

5.  PD-L1 Improves Motor Function and Alleviates Neuropathic Pain in Male Mice After Spinal Cord Injury by Inhibiting MAPK Pathway.

Authors:  Fanqi Kong; Kaiqiang Sun; Jian Zhu; Fudong Li; Feng Lin; Xiaofei Sun; Xi Luo; Changzhen Ren; Lantao Lu; ShuJie Zhao; Jingchuan Sun; Yuan Wang; Jiangang Shi
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.